Published in PLoS One on May 17, 2010
Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine (2012) 1.10
Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy. Crit Rev Oncog (2014) 0.81
MRl of prostate cancer antigen expression for diagnosis and immunotherapy. PLoS One (2012) 0.81
Advances in Molecular Imaging Strategies for In Vivo Tracking of Immune Cells. Biomed Res Int (2016) 0.77
Molecular imaging of bacterial infections in vivo: the discrimination of infection from inflammation. Informatics (MDPI) (2014) 0.77
Use of Nanoparticle Contrast Agents for Cell Tracking with Computed Tomography. Bioconjug Chem (2017) 0.75
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol (2000) 6.90
High gradient magnetic cell separation with MACS. Cytometry (1990) 6.69
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Sequential therapies for proliferative lupus nephritis. N Engl J Med (2004) 5.96
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum (2006) 5.68
Bioluminescent indicators in living mammals. Nat Med (1998) 4.71
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng (2006) 3.67
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum (2004) 3.35
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00
Fluorescent dyes for lymphocyte migration and proliferation studies. Immunol Cell Biol (1999) 2.91
In vivo MRI cell tracking: clinical studies. AJR Am J Roentgenol (2009) 2.85
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum (2004) 2.23
Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum (2005) 2.01
Molecular imaging: looking at problems, seeing solutions. Science (2003) 1.93
Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials (2008) 1.91
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis (2002) 1.74
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol (2005) 1.64
Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol (2005) 1.61
Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum (2002) 1.48
Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood (2000) 1.47
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol (2004) 1.44
Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides. Blood (2004) 1.35
Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol (2008) 1.34
Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis (2008) 1.34
Comparison of optical bioluminescence reporter gene and superparamagnetic iron oxide MR contrast agent as cell markers for noninvasive imaging of cardiac cell transplantation. Mol Imaging Biol (2008) 1.27
Why can't we find a new treatment for SLE? J Autoimmun (2009) 1.15
A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol (2008) 1.13
Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry (2003) 1.12
B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J Immunol (2008) 1.11
IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology (1999) 1.10
Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve (2003) 1.00
Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol (2000) 1.00
A method for labeling cells for positron emission tomography (PET) studies. J Immunol Methods (1994) 0.98
CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain. Int Immunol (1997) 0.97
In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma. Neuroimage (2007) 0.93
Feridex-labeled mesenchymal stem cells: cellular differentiation and MR assessment in a canine myocardial infarction model. Acad Radiol (2005) 0.92
Multiplexed labeling of samples with cell tracking dyes facilitates rapid and accurate internally controlled calcium flux measurement by flow cytometry. J Immunol Methods (2009) 0.87
Lymphocyte tracking and interactions in secondary lymphoid organs. Inflamm Res (2007) 0.84
Novel lipophilic tracking dyes for monitoring cell proliferation. Immunol Invest (2007) 0.83
Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr Metab Immune Disord Drug Targets (2006) 0.82
Mouse splenic B lymphocyte activation using different activation stimuli induces in vitro splicing of tumor necrosis factor-alpha nuclear pre-mRNA. Mol Immunol (2006) 0.78
Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng (2006) 3.67
Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science (2012) 2.73
Dual FRET molecular beacons for mRNA detection in living cells. Nucleic Acids Res (2004) 2.68
Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res (2005) 2.67
Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials (2008) 1.91
A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. Sci Transl Med (2011) 1.69
Fluorescent probes for live-cell RNA detection. Annu Rev Biomed Eng (2009) 1.59
Imaging individual microRNAs in single mammalian cells in situ. Nucleic Acids Res (2009) 1.55
TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol (2007) 1.42
Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med (2011) 1.38
Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol (2002) 1.29
pH-titratable superparamagnetic iron oxide for improved nanoparticle accumulation in acidic tumor microenvironments. ACS Nano (2011) 1.21
Gadolinium-conjugated dendrimer nanoclusters as a tumor-targeted T1 magnetic resonance imaging contrast agent. Angew Chem Int Ed Engl (2010) 1.19
The role of toll-like receptors in systemic lupus erythematosus. Springer Semin Immunopathol (2006) 1.16
Efficient cytosolic delivery of molecular beacon conjugates and flow cytometric analysis of target RNA. Nucleic Acids Res (2008) 1.16
Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization. PLoS One (2013) 1.16
The Mer receptor tyrosine kinase is expressed on discrete macrophage subpopulations and mainly uses Gas6 as its ligand for uptake of apoptotic cells. Clin Immunol (2009) 1.16
RS rearrangement frequency as a marker of receptor editing in lupus and type 1 diabetes. J Exp Med (2008) 1.14
A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol (2008) 1.13
Avoiding false-positive signals with nuclease-vulnerable molecular beacons in single living cells. Nucleic Acids Res (2007) 1.12
Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin Immunol (2008) 1.11
B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J Immunol (2008) 1.11
Metabolic imaging of tumors using intrinsic and extrinsic fluorescent markers. Biosens Bioelectron (2004) 1.10
Effect of ligand density, receptor density, and nanoparticle size on cell targeting. Nanomedicine (2012) 1.10
Paramagnetic porous polymersomes. Langmuir (2008) 1.09
Chronic graft-versus-host in Ig knockin transgenic mice abrogates B cell tolerance in anti-double-stranded DNA B cells. J Immunol (2002) 1.05
The Mer receptor tyrosine kinase is required for the loss of B cell tolerance in the chronic graft-versus-host disease model of systemic lupus erythematosus. J Immunol (2008) 1.04
T cell-independent spontaneous loss of tolerance by anti-double-stranded DNA B cells in C57BL/6 mice. J Immunol (2008) 1.04
Imaging circulating cells and lymphoid tissues with iron oxide nanoparticles. Hematology Am Soc Hematol Educ Program (2009) 1.03
Secondary heavy chain rearrangement: a mechanism for generating anti-double-stranded DNA B cells. J Exp Med (2003) 1.03
In vivo imaging of cancer biomarkers using activatable molecular probes. Cancer Biomark (2008) 1.01
B cell receptor editing in tolerance and autoimmunity. Ann N Y Acad Sci (2011) 1.01
Gold-loaded polymeric micelles for computed tomography-guided radiation therapy treatment and radiosensitization. ACS Nano (2014) 1.01
ICP-MS analysis of lanthanide-doped nanoparticles as a non-radiative, multiplex approach to quantify biodistribution and blood clearance. Biomaterials (2011) 1.00
Porous Polymersomes with Encapsulated Gd-labeled Dendrimers as Highly Efficient MRI Contrast Agents. Adv Funct Mater (2009) 1.00
Gd-based macromolecules and nanoparticles as magnetic resonance contrast agents for molecular imaging. Curr Top Med Chem (2013) 0.99
An intein-mediated site-specific click conjugation strategy for improved tumor targeting of nanoparticle systems. Small (2010) 0.97
Disrupted Mer receptor tyrosine kinase expression leads to enhanced MZ B-cell responses. J Autoimmun (2010) 0.96
Emerging role of radiolabeled nanoparticles as an effective diagnostic technique. EJNMMI Res (2012) 0.96
Assessing the sensitivity of commercially available fluorophores to the intracellular environment. Anal Chem (2008) 0.96
Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms. Am J Pathol (2007) 0.96
Improved tumor targeting of polymer-based nanovesicles using polymer-lipid blends. Bioconjug Chem (2011) 0.96
Ratiometric bimolecular beacons for the sensitive detection of RNA in single living cells. Nucleic Acids Res (2010) 0.95
Comparative analysis of nanoparticle-antibody conjugations: carbodiimide versus click chemistry. Mol Imaging (2009) 0.93
Sub-cellular trafficking and functionality of 2'-O-methyl and 2'-O-methyl-phosphorothioate molecular beacons. Nucleic Acids Res (2009) 0.92
The role of host CD4 T cells in the pathogenesis of the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol (2005) 0.90
A protective role of Mer receptor tyrosine kinase in nephrotoxic serum-induced nephritis. Clin Immunol (2010) 0.89
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma. Cancer Biol Ther (2009) 0.89
Mitomycin C potentiates TRAIL-induced apoptosis through p53-independent upregulation of death receptors: evidence for the role of c-Jun N-terminal kinase activation. Cell Cycle (2012) 0.89
Superparamagnetic iron oxide-enhanced magnetic resonance imaging of neuroinflammation in a rat model of radicular pain. Mol Imaging (2011) 0.87
Gd-labeled glycol chitosan as a pH-responsive magnetic resonance imaging agent for detecting acidic tumor microenvironments. J Med Chem (2013) 0.86
Firefly luciferase and RLuc8 exhibit differential sensitivity to oxidative stress in apoptotic cells. PLoS One (2011) 0.86
Biodegradable polydisulfide dendrimer nanoclusters as MRI contrast agents. ACS Nano (2012) 0.85
Sortase-tag expressed protein ligation: combining protein purification and site-specific bioconjugation into a single step. Anal Chem (2013) 0.84
Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus. J Immunol (2006) 0.84
The role of antibodies in inflammatory arthritis. Immunol Rev (2010) 0.83
Quantitative assessment of ratiometric bimolecular beacons as a tool for imaging single engineered RNA transcripts and measuring gene expression in living cells. Nucleic Acids Res (2013) 0.83
Analgesic effect of iridoid glycosides from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on spared nerve injury rat model of neuropathic pain. Pharmacol Biochem Behav (2012) 0.83
Engineering nanostructured probes for sensitive intracellular gene detection. Mech Chem Biosyst (2004) 0.82
Selection of individual VH genes occurs at the pro-B to pre-B cell transition. J Immunol (2011) 0.82
Examination of folate-targeted liposomes with encapsulated poly(2-propylacrylic acid) as a pH-responsive nanoplatform for cytosolic drug delivery. Small (2010) 0.82
Delivery of molecular beacons for live-cell imaging and analysis of RNA. Methods Mol Biol (2011) 0.82
Association of leukocyte CR1 gene transcription with the disease severity and renal involvement in systemic lupus erythematosus. Lupus (2005) 0.82
FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. Int J Oncol (2011) 0.81
Antibodies in a heavy chain knock-in mouse exhibit characteristics of early heavy chain rearrangement. J Immunol (2009) 0.81
Quantification of miRNA abundance in single cells using locked nucleic acid-FISH and enzyme-labeled fluorescence. Methods Mol Biol (2011) 0.80
Association of complement receptor 1 (CR1, CD35, C3b/C4b receptor) density polymorphism with glomerulonephritis in Indian subjects. Mol Immunol (2004) 0.80
Intrinsic unresponsiveness of Mertk-/- B cells to chronic graft-versus-host disease is associated with unmodulated CD1d expression. J Autoimmun (2012) 0.80
Nanodisco balls: control over surface versus core loading of diagnostically active nanocrystals into polymer nanoparticles. ACS Nano (2014) 0.79
A multifunctional nanoplatform for imaging, radiotherapy, and the prediction of therapeutic response. Small (2014) 0.79
Facile method for the site-specific, covalent attachment of full-length IgG onto nanoparticles. Small (2014) 0.79
B cells require "nurturing" by CD4 T cells during development in order to respond in chronic graft-versus-host model of systemic lupus erythematosus. Clin Immunol (2010) 0.79
B-cell tolerance defects in the B6.Aec1/2 mouse model of Sjögren's syndrome. J Clin Immunol (2012) 0.79
KRN/I-Ag7 mouse arthritis is independent of complement C3. J Clin Immunol (2011) 0.79
Stabilized porous liposomes with encapsulated Gd-labeled dextran as a highly efficient MRI contrast agent. Chem Commun (Camb) (2014) 0.78
Suicide gene delivery by calcium phosphate nanoparticles: a novel method of targeted therapy for gastric cancer. Cancer Biol Ther (2006) 0.78
Chronic graft-versus-host reaction is associated with a decrease in Ig light chain receptor editing in bone marrow self-reactive B cells. Eur J Immunol (2004) 0.78
Mature B cells preferentially lose tolerance in the chronic graft-versus-host disease model of systemic lupus erythematosus. J Immunol (2007) 0.78
Anti-inflammatory and immunomodulatory effects of iridoid glycosides from Paederia scandens (LOUR.) MERRILL (Rubiaceae) on uric acid nephropathy rats. Life Sci (2012) 0.78
Biochemical composition and antioxidant capacity of extracts from Podophyllum hexandrum rhizome. BMC Complement Altern Med (2012) 0.78
Assessment of global cardiac uptake of radiolabeled iron oxide nanoparticles in apolipoprotein-E-deficient mice: implications for imaging cardiovascular inflammation. Mol Imaging Biol (2014) 0.77
PLA2-responsive and SPIO-loaded phospholipid micelles. Chem Commun (Camb) (2015) 0.77
A novel chitosan-hydrogel-based nanoparticle delivery system for local inner ear application. Otol Neurotol (2015) 0.77
Immunomodulatory effect of DDT (bis[4-chlorophenyl]-1,1,1-trichloroethane) on complement system and macrophages. Toxicology (2008) 0.77
Iron chelator-based amplification strategy for improved targeting of transferrin receptor with SPIO. Cancer Biol Ther (2008) 0.77
Absence of CD59 exacerbates systemic autoimmunity in MRL/lpr mice. J Immunol (2012) 0.76
Two-photon imaging of multicellular tumor spheroids: a novel method for evaluating the efficacy of CDC25 phosphatase inhibitors. Cancer Biol Ther (2009) 0.75
Optimization of photoactive protein Z for fast and efficient site-specific conjugation of native IgG. Bioconjug Chem (2014) 0.75
Superparamagnetic iron oxide nanoparticle micelles stabilized by recombinant oleosin for targeted magnetic resonance imaging. Small (2014) 0.75
Improving nanoparticle delivery with anti-angiogenesis therapy. Nanomedicine (Lond) (2012) 0.75
Enhancing the cell uptake of nanoparticles within tumors. Nanomedicine (Lond) (2012) 0.75
Synergizing radiation therapy with drug-loaded nanovectors. Nanomedicine (Lond) (2012) 0.75
Targeted and drug-loaded micelles. Nanomedicine (Lond) (2012) 0.75
Biodistribution, Clearance, and Toxicology of Polymeric Micelles Loaded with 0.9 or 5 nm Gold Nanoparticles. J Biomed Nanotechnol (2015) 0.75
Tumor necrosis factor receptor-associated factor 1 influences KRN/I-Ag7 mouse arthritis autoantibody production. J Clin Immunol (2013) 0.75
Simultaneous quantification of tumor uptake for targeted and nontargeted liposomes and their encapsulated contents by ICPMS. Anal Chem (2012) 0.75